Skip to main content
NCBI home page
Transactions of the American Ophthalmological Society logoLink to Transactions of the American Ophthalmological Society
. 1995;93:421–441.

Topical apraclonidine hydrochloride in eyes with poorly controlled glaucoma. The Apraclonidine Maximum Tolerated Medical Therapy Study Group.

A L Robin 1, R Ritch 1, D Shin 1, B Smythe 1, T Mundorf 1, R P Lehmann 1
PMCID: PMC1312069  PMID: 8719690

Abstract

OBJECT: We determined whether the addition of topical apraclonidine hydrochloride to eyes receiving maximal medical therapy, with inadequate intraocular pressure (IOP) control, and scheduled to undergo surgery, could adequately lower IOP, postponing the need for surgical intervention. DESIGN: A prospective 90 day, multi-centered, placebo-controlled, doublemasked parallel study. PATIENTS: We enrolled 174 glaucoma patients with inadequate IOP control on maximally tolerated medical therapy. All were candidates for either laser trabeculoplasty or invasive surgical intervention. We enrolled only one eye per patient. INTERVENTIONS: We continued to administer maximum-tolerated medical therapy for glaucoma. Patients took the study medication every eight hours. Study medications were either apraclonidine hydrochloride 0.5% or placebo (apraclonidine's vehicle). MAJOR OUTCOME MEASURES: We evaluated IOP, IOP change from baseline, and the number of eyes requiring surgery after the addition of study medication. RESULTS: Sixty one percent of patients treated with apraclonidine maintained adequate IOP control throughout the study, avoiding additional surgery compared to 33.9% patients treated with placebo (P < .001). Apraclonidine treatment resulted in significantly more patients achieving either an additional > or = 20% reduction in IOP from baseline (resulting in an IOP < or = 20 mm Hg) (P < 0.05). The most common ocular complications were conjunctival hyperemia (12.6%), itching and foreign body sensation (6.8%), and tearing (4.5%). The most frequent non-ocular adverse events related to apraclonidine were dry mouth (4.5%) and unusual taste perception (2.2%). CONCLUSIONS: Apraclonidine appears safe and efficacious. It significantly lowered IOP when used in combination with a patient's maximum tolerated medical therapy. This delayed or prevented further glaucoma surgery for at least 90 days in approximately 60% of treated patients.

Full text

PDF
421

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrams D. A., Robin A. L., Crandall A. S., Caldwell D. R., Schnitzer D. B., Pollack I. P., Rader J. E., Reaves T. A., Jr A limited comparison of apraclonidine's dose response in subjects with normal or increased intraocular pressure. Am J Ophthalmol. 1989 Sep 15;108(3):230–237. doi: 10.1016/0002-9394(89)90111-6. [DOI] [PubMed] [Google Scholar]
  2. Abrams D. A., Robin A. L., Pollack I. P., deFaller J. M., DeSantis L. The safety and efficacy of topical 1% ALO 2145 (p-aminoclonidine hydrochloride) in normal volunteers. Arch Ophthalmol. 1987 Sep;105(9):1205–1207. doi: 10.1001/archopht.1987.01060090063028. [DOI] [PubMed] [Google Scholar]
  3. Ashburn F. S., Jr, Goldberg I., Kass M. A. Compliance with ocular therapy. Surv Ophthalmol. 1980 Jan-Feb;24(4):237–248. doi: 10.1016/0039-6257(80)90045-4. [DOI] [PubMed] [Google Scholar]
  4. Brown R. H., Stewart R. H., Lynch M. G., Crandall A. S., Mandell A. I., Wilensky J. T., Schwartz A. L., Gaasterland D. E., DeFaller J. M., Higginbotham E. J. ALO 2145 reduces the intraocular pressure elevation after anterior segment laser surgery. Ophthalmology. 1988 Mar;95(3):378–384. doi: 10.1016/s0161-6420(88)33185-4. [DOI] [PubMed] [Google Scholar]
  5. Coleman A. L., Robin A. L., Pollack I. P., Rudikoff M. T., Enger C., Mayer P. R. Cardiovascular and intraocular pressure effects and plasma concentrations of apraclonidine. Arch Ophthalmol. 1990 Sep;108(9):1264–1267. doi: 10.1001/archopht.1990.01070110080029. [DOI] [PubMed] [Google Scholar]
  6. Gharagozloo N. Z., Brubaker R. F. Effect of apraclonidine in long-term timolol users. Ophthalmology. 1991 Oct;98(10):1543–1546. doi: 10.1016/s0161-6420(91)32106-7. [DOI] [PubMed] [Google Scholar]
  7. Gharagozloo N. Z., Relf S. J., Brubaker R. F. Aqueous flow is reduced by the alpha-adrenergic agonist, apraclonidine hydrochloride (ALO 2145). Ophthalmology. 1988 Sep;95(9):1217–1220. doi: 10.1016/s0161-6420(88)33038-1. [DOI] [PubMed] [Google Scholar]
  8. Granström P. A. Glaucoma patients not compliant with their drug therapy: clinical and behavioural aspects. Br J Ophthalmol. 1982 Jul;66(7):464–470. doi: 10.1136/bjo.66.7.464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Granström P. A., Norell S. Visual ability and drug regimen: relation to compliance with glaucoma therapy. Acta Ophthalmol (Copenh) 1983 Apr;61(2):206–219. doi: 10.1111/j.1755-3768.1983.tb01414.x. [DOI] [PubMed] [Google Scholar]
  10. Jampel H. D., Robin A. L., Quigley H. A., Pollack I. P. Apraclonidine. A one-week dose-response study. Arch Ophthalmol. 1988 Aug;106(8):1069–1073. doi: 10.1001/archopht.1988.01060140225029. [DOI] [PubMed] [Google Scholar]
  11. Morrison J. C., Robin A. L. Adjunctive glaucoma therapy. A comparison of apraclonidine to dipivefrin when added to timolol maleate. Ophthalmology. 1989 Jan;96(1):3–7. doi: 10.1016/s0161-6420(89)32977-0. [DOI] [PubMed] [Google Scholar]
  12. Nagasubramanian S., Hitchings R. A., Demailly P., Chuniaud M., Pannarale M. R., Pecori-Giraldi J., Stodtmeister R., Parsons D. G. Comparison of apraclonidine and timolol in chronic open-angle glaucoma. A three-month study. Ophthalmology. 1993 Sep;100(9):1318–1323. doi: 10.1016/s0161-6420(13)31818-1. [DOI] [PubMed] [Google Scholar]
  13. Pollack I. P., Brown R. H., Crandall A. S., Robin A. L., Stewart R. H., White G. L. Prevention of the rise in intraocular pressure following neodymium-YAG posterior capsulotomy using topical 1% apraclonidine. Arch Ophthalmol. 1988 Jun;106(6):754–757. doi: 10.1001/archopht.1988.01060130824031. [DOI] [PubMed] [Google Scholar]
  14. Pollack I. P., Robin A. L., Sax H. The effect of argon laser trabeculoplasty on the medical control of primary open-angle glaucoma. Ophthalmology. 1983 Jul;90(7):785–789. doi: 10.1016/s0161-6420(83)34487-0. [DOI] [PubMed] [Google Scholar]
  15. Robin A. L., Coleman A. L. Apraclonidine hydrochloride: an evaluation of plasma concentrations, and a comparison of its intraocular pressure lowering and cardiovascular effects to timolol maleate. Trans Am Ophthalmol Soc. 1990;88:149–162. [PMC free article] [PubMed] [Google Scholar]
  16. Robin A. L. Effect of topical apraclonidine on the frequency of intraocular pressure elevations after combined extracapsular cataract extraction and trabeculectomy. Ophthalmology. 1993 May;100(5):628–633. doi: 10.1016/s0161-6420(93)31603-9. [DOI] [PubMed] [Google Scholar]
  17. Robin A. L., Pollack I. P., House B., Enger C. Effects of ALO 2145 on intraocular pressure following argon laser trabeculoplasty. Arch Ophthalmol. 1987 May;105(5):646–650. doi: 10.1001/archopht.1987.01060050064039. [DOI] [PubMed] [Google Scholar]
  18. Robin A. L., Pollack I. P., deFaller J. M. Effects of topical ALO 2145 (p-aminoclonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy. Arch Ophthalmol. 1987 Sep;105(9):1208–1211. doi: 10.1001/archopht.1987.01060090066029. [DOI] [PubMed] [Google Scholar]
  19. Robin A. L. The role of apraclonidine hydrochloride in laser therapy for glaucoma. Trans Am Ophthalmol Soc. 1989;87:729–761. [PMC free article] [PubMed] [Google Scholar]
  20. Schwartz A. L., Love D. C., Schwartz M. A. Long-term follow-up of argon laser trabeculoplasty for uncontrolled open-angle glaucoma. Arch Ophthalmol. 1985 Oct;103(10):1482–1484. doi: 10.1001/archopht.1985.01050100058018. [DOI] [PubMed] [Google Scholar]
  21. Shingleton B. J., Richter C. U., Dharma S. K., Tong L., Bellows A. R., Hutchinson B. T., Glynn R. J. Long-term efficacy of argon laser trabeculoplasty. A 10-year follow-up study. Ophthalmology. 1993 Sep;100(9):1324–1329. doi: 10.1016/s0161-6420(93)31480-6. [DOI] [PubMed] [Google Scholar]
  22. Spaeth G. L., Baez K. A. Argon laser trabeculoplasty controls one third of cases of progressive, uncontrolled, open angle glaucoma for 5 years. Arch Ophthalmol. 1992 Apr;110(4):491–494. doi: 10.1001/archopht.1992.01080160069032. [DOI] [PubMed] [Google Scholar]
  23. Vocci M. J., Robin A. L., Wahl J. C., Mayer P., Graves A., York B., Enger C., Sutton J. Reformulation and drop size of apraclonidine hydrochloride. Am J Ophthalmol. 1992 Feb 15;113(2):154–160. doi: 10.1016/s0002-9394(14)71527-2. [DOI] [PubMed] [Google Scholar]
  24. Yaldo M. K., Shin D. H., Parrow K. A., Lee S. H., Lee S. Y. Additive effect of 1% apraclonidine hydrochloride to nonselective beta-blockers. Ophthalmology. 1991 Jul;98(7):1075–1078. doi: 10.1016/s0161-6420(91)32189-4. [DOI] [PubMed] [Google Scholar]
  25. Zimmerman T. J., Zalta A. H. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983 Dec;28 (Suppl):252–258. doi: 10.1016/0039-6257(83)90142-x. [DOI] [PubMed] [Google Scholar]

Articles from Transactions of the American Ophthalmological Society are provided here courtesy of American Ophthalmological Society

RESOURCES